Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TSN084 Tablets in Patients With Advanced Malignant Tumors.

NCT06386705 is registered in ClinicalTrials.gov with Tyligand Bioscience (Shanghai) Limited as lead sponsor.

NCT NCT06386705
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06386705 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TSN084 Tablets in Patients With Advanced Malignant Tumors.
Lead sponsor
Tyligand Bioscience (Shanghai) Limited
Phase
Phase 1
Overall status
Unknown status
Start date
July 20, 2022
Completion date
June 30, 2026
Enrollment
114 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

malignant neoplasm